Utah Medical Marijuana Sales Reach $16.3 Million in March, Patient Count Climbs Above 112,000
- Utah’s medical marijuana program saw growth in March with 112,093 active patients, increased from 110,487 in February, and a strong network of 1,018 recommending providers and licensed agents across various roles.
- Patient demographics are stable, with the largest group aged 31-40 (26.13%), and persistent pain remains the leading qualifying condition for 97,530 patients, followed by PTSD and other ailments like cancer and epilepsy.
- March sales reached $16.26 million, surpassing previous months, with cartridges and vape pens as the top-selling category, followed by flower and infused edibles; total 2026 sales have nearly hit $50 million.
- Supply activity included harvesting over 10,000 plants and producing 7.9 million grams of wet biomass, alongside high volumes of processed products, reflecting ongoing strong demand and patient engagement in the program.
Utah’s medical marijuana program continued its upward trajectory in March, with patient counts rising and monthly sales surpassing January and February’s totals, according to the state’s latest monthly report.
As of March 31, Utah has 112,093 patients with active medical cannabis cards, an increase from the 110,487 reported the previous month. The program also includes 1,018 registered recommending medical providers, along with hundreds of licensed agents across cultivation, processing, pharmacy, and delivery roles.
Patient demographics remain largely consistent. Those aged 31 to 40 continue to make up the largest share at 26.13%, followed by 41 to 50 at 22.39% and 21 to 30 at 22.02%. Individuals 51 to 64 account for 18.40%, while patients over 65 represent 10.99%. Those under 21 remain well under 1% of the total.
Persistent pain remains overwhelmingly the most common qualifying condition, with 97,530 patients listing it. PTSD follows with 5,690 patients, while conditions such as cancer (2,096), nausea (2,435), epilepsy (725), and Crohn’s disease (576) make up smaller portions of the total patient base.
Sales climbed notably in March. Total medical marijuana purchases reached $16,259,200, up from just over $15 million in February. Cartridges and vape pens remained the dominant category, generating $7,955,200 in sales. Flower followed at $5,188,800, while infused edibles brought in $2,874,000. Infused non-edible products accounted for $116,200, and non-medicated items such as devices and batteries added another $125,000.
Total medical cannabis sales in Utah for 2026 have now reached nearly $50 million.
Patient engagement remained strong. Over the past 90 days, 75,893 patients made at least one purchase, with more than 30,000 making four or more purchases during that timeframe, underscoring consistent participation across the program.
On the supply side, cultivators harvested over 10,007 plants in March across 289 batches, producing more than 7.9 million grams of wet cannabis biomass. Processors also continued to move large volumes of products to pharmacies, including 165,396 cartridges and pens, 93,411 units of flower, and over 101,000 infused edible products.
The March data points to continued growth across Utah’s medical marijuana market, with rising patient enrollment, increased sales, and steady demand across key product categories.